Glasová M, Koníková E, Stasáková J, Babusíková O
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovakia.
Neoplasma. 1998;45(2):88-95.
We investigated the expression-percentage as well as MESF values ("molecules of equivalent soluble fluorochrom" that represent approximately the density of marker expression) of HLA-DR, CD71 and CD38 markers in some human leukemias (ALL, AML, CLL, CML) and lymphomas. They are non-lineage restricted and are supposed to be activation markers except for cases where they represent pathological phenotype like HLA-DR in pre B-ALL, CD38 in some M0 AML or in plasmocytoma or CD38 and CD71 in less mature T-ALL. We used flow cytometry, immunofluorescent staining, DNA staining by propidium iodide and quantification by calibration particles. We demonstrated increased MESF values of HLA-DR compared with controls in all investigated disorders, what could have a prognostic value. We demonstrated significantly higher MESF values of HLA-DR in cALL (37,300-46,000) in comparison with AML (9400-12,400), what could represent another important parameter when distinguishing between these two groups of leukemia. In cells of CML patients with lower CD38% and CD71% increased MESF values (5100 for CD38 and 7900 for CD71), were found while in some T-ALL, AML and cALL patients with high percentages of CD71 and CD38 there were lower MESF values what could indicate a possible connection of higher stage of cell maturation with increased density of CD38 and CD71 markers. We investigated possible relationship between percentage of expression of HLA-DR, CD38 and CD71 and proliferation rate by DNA analysis of the cell cycle. In a group of non-Hodgkin's lymphoma patients, there was no significant increase of proliferation index of malignant cells compared with control. The correlation between percentage of expression of mentioned parameters and proliferation index was not significant. In one patient with Burkitt's lymphoma we demonstrated significant increase of proliferation index of CD71+ subpopulation compared with CD71- one, what indicates that in aggressive form of NHL CD71 can be evaluated not only as activation but also as proliferation marker.
我们研究了某些人类白血病(急性淋巴细胞白血病、急性髓细胞白血病、慢性淋巴细胞白血病、慢性髓细胞白血病)和淋巴瘤中HLA - DR、CD71和CD38标志物的表达百分比以及MESF值(“等效可溶性荧光染料分子”,大致代表标志物表达的密度)。它们不受谱系限制,除了在某些情况下代表病理表型,如前B淋巴细胞白血病中的HLA - DR、某些M0急性髓细胞白血病或浆细胞瘤中的CD38,或较不成熟T淋巴细胞白血病中的CD38和CD71,其他情况下都被认为是激活标志物。我们使用了流式细胞术、免疫荧光染色、碘化丙啶DNA染色以及通过校准颗粒进行定量分析。我们发现,与对照组相比,在所有研究的疾病中HLA - DR的MESF值均升高,这可能具有预后价值。与急性髓细胞白血病(9400 - 12,400)相比,我们发现普通型急性淋巴细胞白血病中HLA - DR的MESF值显著更高(37,300 - 46,000),这在区分这两组白血病时可能是另一个重要参数。在慢性髓细胞白血病患者的细胞中,CD38%和CD 的MESF值升高(CD38为5100,CD71为7900),而在一些CD71和CD38百分比高的T淋巴细胞白血病、急性髓细胞白血病和普通型急性淋巴细胞白血病患者中,MESF值较低,这可能表明细胞成熟度较高阶段与CD38和CD71标志物密度增加之间存在可能的联系。我们通过细胞周期的DNA分析研究了HLA - DR、CD38和CD71表达百分比与增殖率之间的可能关系。在一组非霍奇金淋巴瘤患者中,与对照组相比,恶性细胞的增殖指数没有显著增加。上述参数的表达百分比与增殖指数之间的相关性不显著。在一名伯基特淋巴瘤患者中,我们发现CD71 +亚群的增殖指数与CD71 -亚群相比显著增加,这表明在侵袭性非霍奇金淋巴瘤中,CD71不仅可以作为激活标志物,还可以作为增殖标志物进行评估。